H
H.G.F. Burnand
Researcher at Cheltenham General Hospital
Publications - 7
Citations - 205
H.G.F. Burnand is an academic researcher from Cheltenham General Hospital. The author has contributed to research in topics: Hip fracture & Mortality rate. The author has an hindex of 4, co-authored 7 publications receiving 180 citations.
Papers
More filters
Journal ArticleDOI
Early and ultra-early surgery in hip fracture patients improves survival.
C.E. Uzoigwe,H.G.F. Burnand,C.L. Cheesman,Douglas Osaro Aghedo,Murtuza Faizi,R. G. Middleton +5 more
TL;DR: Examining whether surgery before a 36h watershed improves survival and the effect of various parameters on in-patient mortality found that ultra-early surgery (within 12h) reduces risk of in-hospital mortality andeditious surgery is associated with improved patient survival.
Journal ArticleDOI
Human‐factors training for surgical trainees
TL;DR: Human‐factors training has an increasing role to play in enhancing patient safety and reducing medical errors, and is currently aimed at consultants, senior trainees and theatre teams.
Journal ArticleDOI
Serum lactate is a prognostic indicator in patients with hip fracture.
Chika E. Uzoigwe,Muralidharan Venkatesan,Robert H. Smith,H.G.F. Burnand,P.S. Young,C.L. Cheesman,R. G. Middleton +6 more
TL;DR: In this article, admission serum venous lactate can predict in-hospital mortality in patients with hip fractures and a critical threshold of 3 mmol/L with respect to the influence on mortality was identified.
Journal ArticleDOI
Surgical training in your hands: organising a skills course.
H.G.F. Burnand,Jon Mutimer +1 more
TL;DR: The advent of simulated surgical skills courses has brought dynamic changes to the traditional approach to acquiring practical skills in surgery, leading to changes in the way patients are taught and cared for.
Journal ArticleDOI
Bilateral subtrochanteric fractures in tumour-induced osteomalacia caused by a nasal haemangiopericytoma.
TL;DR: Investigation of bilateral insufficiency fractures of the proximal femur often have a pathological basis and should include serum levels of fibroblast growth factor 23 (FGF23) which is a peptide hormone secreted by mesenchymal tumours.